open access

Vol 56, No 3 (2005)
Congressional papers
Published online: 2006-03-24
Submitted: 2013-02-15
Get Citation

Medullary thyroid carcinoma: from molecular studies to clinical decision

Jan Włoch, Małgorzata Oczko-Wojciechowska, Sylwia Szpak-Ulczok, Barbara Jarząb
Endokrynologia Polska 2005;56(3):362-369.

open access

Vol 56, No 3 (2005)
Congressional papers
Published online: 2006-03-24
Submitted: 2013-02-15

Abstract

The paper is focused on guidelines of practice in inherited medullary thyroid cancer, diagnosed on the basis of DNA analysis. Identification of RET mutation implies further steps of diagnostic procedure, some of them – USG, FNAB and calcitonin level tests – are common fro all types of mutation, other are related to ascertained type of mutation. In asymptomatic RET mutation carriers, prophylactic thyroidectomy is indicated.
In MEN2B inherited cancer reveals its symptoms quickly and shows dynamic progress. In MEN2A/FMTC the clinical picture is diversified – in some patients the course of disease is mild, however in some other cases the progression of disease and even death occur regardless of the proper treatment. Unfortunately, there are no molecular prognostic markers in medullary thyroid carcinoma.
Recent papers and also our own unpublished results show that gene expression profile, is similar in MEN2A and sporadic cancer. This group differs from MEN2B by its expression profile.
In conclusion it is to be emphasized that although inherited medullary thyroid carcinoma is a rare disease, the diagnostic algorithm is well established and maximizes the chance for early diagnosis. Moreover, it needs to be stressed that DNA analysis results inform us not only about the necessity of further therapy, but also suggest different ways of proceeding in particular type of mutation.

Abstract

The paper is focused on guidelines of practice in inherited medullary thyroid cancer, diagnosed on the basis of DNA analysis. Identification of RET mutation implies further steps of diagnostic procedure, some of them – USG, FNAB and calcitonin level tests – are common fro all types of mutation, other are related to ascertained type of mutation. In asymptomatic RET mutation carriers, prophylactic thyroidectomy is indicated.
In MEN2B inherited cancer reveals its symptoms quickly and shows dynamic progress. In MEN2A/FMTC the clinical picture is diversified – in some patients the course of disease is mild, however in some other cases the progression of disease and even death occur regardless of the proper treatment. Unfortunately, there are no molecular prognostic markers in medullary thyroid carcinoma.
Recent papers and also our own unpublished results show that gene expression profile, is similar in MEN2A and sporadic cancer. This group differs from MEN2B by its expression profile.
In conclusion it is to be emphasized that although inherited medullary thyroid carcinoma is a rare disease, the diagnostic algorithm is well established and maximizes the chance for early diagnosis. Moreover, it needs to be stressed that DNA analysis results inform us not only about the necessity of further therapy, but also suggest different ways of proceeding in particular type of mutation.
Get Citation

Keywords

medullary thyroid carcinoma; protooncogene RET mutations; prophylactic thyroidectomy

About this article
Title

Medullary thyroid carcinoma: from molecular studies to clinical decision

Journal

Endokrynologia Polska

Issue

Vol 56, No 3 (2005)

Pages

362-369

Published online

2006-03-24

Bibliographic record

Endokrynologia Polska 2005;56(3):362-369.

Keywords

medullary thyroid carcinoma
protooncogene RET mutations
prophylactic thyroidectomy

Authors

Jan Włoch
Małgorzata Oczko-Wojciechowska
Sylwia Szpak-Ulczok
Barbara Jarząb

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl